OncoCyte Corporation (OCX) - מזומנים למניה אחת

Following the restructuring, OncoCyte Corporation has focused on monetizing its core products through distribution networks. Fluctuations in cash per share demonstrate the current liquidity reserve, with the metric currently standing at 1.07. The company generates revenue from biomarker laboratory tests for lung cancer therapy, targeting the growing liquid biopsy market and oncologists' needs for early tumor screening.
פילוחים אנליטיים של חברת OncoCyte Corporation (OCX)

This metric determines the portion of the net cash reserve attributable to a single common share. By analyzing the change in cash per share, an investor assesses liquidity trends and the company's ability to fund growth. The metric confirms operational stability by comparing capital against the volume of issuance. For OncoCyte Corporation (OCX), this is critical when supporting high-tech laboratories in the US. The automation of diagnostic centers requires stable cash funding.